Squarepoint
SMMT icon

Squarepoint’s Summit Therapeutics SMMT Stock Holding History

Squarepoint’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-781,900
Closed -$16.2M – 4842
2025
Q3 		$16.2M Sell
781,900
-87,800
-10% -$2.13M 0.02% 849
2025
Q2 		$18.5M Buy
869,700
+847,700
+3,853% +$19.3M 0.02% 801
2025
Q1 		$424K Sell
22,000
-14,200
-39% -$285K ﹤0.01% 3458
2024
Q4 		$646K Buy
+36,200
New +$702K ﹤0.01% 3492

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Squarepoint's SMMT Position: Q1 2026 in Review

Squarepoint reduced its Summit Therapeutics (SMMT) stake by 14% in Q1 2026, selling an estimated $1.64M and leaving 613,877 shares worth $11.6M. The position accounts for 0.01% of the portfolio, ranked #994.

Squarepoint first reported a position in SMMT in Q4 2020 and has held it in 9 quarters since. The position peaked at $12.5M in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Squarepoint held 613,877 shares of Summit Therapeutics worth $11.6M as of Q1 2026.
  • Squarepoint sold 101,533 Summit Therapeutics shares in Q1 2026, an estimated $1.64M.
  • Summit Therapeutics made up 0.01% of Squarepoint's portfolio in Q1 2026, its #994 holding.
  • Squarepoint first reported a position in Summit Therapeutics in Q4 2020 and has held it in 9 quarters since.
  • Squarepoint's Summit Therapeutics position peaked at $12.5M in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.